Hinge Health Aims for IPO: A Potential Game-Changer in the Healthtech Sector

Hinge Health has taken steps to enter the public market by filing its S-1 documentation for an initial public offering (IPO) on Monday. The company has partnered with investment giants Morgan Stanley, Barclays, and Bank of America for this endeavor.

Should Hinge Health proceed with its public market entry, it would mark the first instance of a healthcare delivery startup going public in almost three years. Recent years have seen a decline in healthcare IPO activity due to the underwhelming performance of companies during the 2021 IPO wave.

Established in San Francisco in 2014, Hinge Health provides online therapy solutions for joint and muscle concerns. The company's shares are anticipated to be listed on the New York Stock Exchange, represented by the symbol 'HNGE'.

Entering the stock market now poses challenges due to current volatility. The Nasdaq and S&P 500 recently fell to their lowest points in months, partly driven by international trade tensions and extensive job reductions in the government sector, raising fears of an economic downturn.

Insights from Hinge Health's Financial Disclosure

Business experts advised that healthcare startups contemplating an IPO should show substantial revenue, achieve profitability, and maintain growth rates above 30% year over year. Hinge Health comes close to meeting these criteria.

In 2024, the company reported earnings of $390 million, which represented a 33% increase from the prior year. Notably, Hinge Health retained an impressive 77% in gross margins after accounting for its service costs.

Although not entirely in the black, the company is on track to profitability, having generated $45 million in free cash flow for 2024, albeit ending the year with a net loss of $11.9 million. This is a significant reduction from the $108 million net loss reported in 2023, attributed to cost-cutting measures including workforce reductions and scaling back marketing expenditures.

Valuation and Market Position

The S-1 filing does not specify a price for its shares. This IPO will challenge their previous valuation of $6.2 billion, achieved in October 2021 during its Series E funding led by Tiger Global and Coatue Management. Since then, the landscape has shifted, with many digital health companies experiencing value declines post-IPO.

By the end of 2024, Hinge Health had accrued $466 million in cash and financial assets. The digital health industry has become more cautious, should Hinge Health aim to surpass its 2021 valuation.

There was a notable agreement for Coatue to repurchase $50 million in shares from Hinge Health before the IPO, though the rationale behind this move was not disclosed.

Strategic Growth and Client Acquisition

Hinge Health targets self-insured employers and collaborates with various health plans and pharmacy benefit managers. Its technology suite, which includes AI-driven motion tracking and an FDA-approved wearable device for pain management, significantly reduces traditional therapy hours by 95%.

While the company plans to expand into other healthcare services, its primary focus is on onboarding and maintaining new clients. By the close of 2024, Hinge Health served over 532,000 members from a potential 20 million and held partnerships with over 2,250 businesses.

Strategically, Hinge Health intends to bolster its presence beyond the United States into international markets, including Europe and Canada.

Bulk investments in sales and marketing characterized their financial strategies between 2023 and 2024, with half or more of total revenue typically devoted to these efforts. However, a reduction was observed in late 2024.

Future Implications in Healthtech IPOs

If successful, Hinge Health's IPO could pave the way for other healthcare technology companies contemplating public listings. Ahead in line might be Omada Health, which filed privately, and Sword Health, a close competitor of Hinge, eyeing public markets as conditions improve.